Magle Chemoswed Holding Valuation

Q: What is the Fair Price of MAGLE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MAGLE (SEK33.6) is trading below our estimate of [[fair value]] (SEK140.58)

Is MAGLE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MAGLE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MAGLE (SEK33.6) is trading below our estimate of fair value (SEK140.58)

Significantly Below Fair Value: MAGLE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MAGLE?

Key metric: As MAGLE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MAGLE. This is calculated by dividing MAGLE's market cap by their current earnings.
What is MAGLE's PE Ratio?
PE Ratio	36.9x
Earnings	SEK 16.75m
Market Cap	SEK 621.98m

MAGLE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.9x
Enterprise Value/EBITDA	18.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does MAGLE's PE Ratio compare to its peers?

The above table shows the PE ratio for MAGLE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	70.2x
GENO Genovis AB (publ.)	65.8x	16.4%	SEK 1.8b
MCAP MedCap	33.3x	n/a	SEK 7.8b
BIOT Biotage	46.6x	19.5%	SEK 12.1b
ALIF B AddLife	135.3x	52.0%	SEK 16.1b
MAGLE Magle Chemoswed Holding	36.9x	n/a	SEK 622.0m

Price-To-Earnings vs Peers: MAGLE is good value based on its Price-To-Earnings Ratio (36.9x) compared to the peer average (70.2x).

Price to Earnings Ratio vs Industry

How does MAGLE's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: MAGLE is good value based on its Price-To-Earnings Ratio (36.9x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is MAGLE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MAGLE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	36.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MAGLE's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£154.7b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,392.50

-1.0%

4.7%

Swedish Orphan Biovitrum

SEK 102.4b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 298.20

-9.1%

23.3%

Ascelia Pharma

SEK 252.2m

A biotech company, focuses on orphan oncology treatments in Sweden.

ACE

SEK 2.63

-0.9%

-9.3%